News

These filings are necessary prior to the anticipated global roll-out of the company’s BioNanoChannel rapid bacteria/microorganism detection technology and also contribute to the protection of NanoLogix’s ongoing Hydrogen

This proof-of-concept study is designed to enroll a total of 180 patients with 120 patients randomized to treatment with retigabine and 60 randomized to placebo treatment for a

The drug, Rh-Apo2L, is produced by genetic engineering and is designed as a highly targeted therapy with direct function on cancer cells. Shanghai Qiaer, Aida’s research subsidiary, has

The study hypothesized that because adhesion of leukemic cells to vascular cells may confer resistance to chemotherapeutic agents, treatment with CA4P would promote leukemic cell death by disrupting

The trial was designed to evaluate the pharmacokinetic and pharmacodynamic response of octreotide implants in patients with acromegaly. The trial evaluated the release effectiveness of both pre-hydrated and

The new drug application (NDA) was submitted by Vanda Pharmaceuticals and includes data from 35 clinical trials and more than 3,000 patients treated with iloperidone. Acceptance of the

The named patient access program (NPAP) is a compassionate use drug supply program administered by the Therapeutic Goods Administration (TGA), under which medical practitioners can legally supply investigational

The study findings demonstrate Hedrin’s superior efficacy compared to malathion, a widely used insecticide treatment in both Europe and North America. These results appeared in the November issue

This blinded, placebo-controlled study assessed symptom scores and treatment outcome two years (range 16 to 27 months) after a single treatment with NX-1207 or placebo. For patients with